About Us

We are a clinical stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells are a distinct T cell population that combine durable memory responses with the rapid cytolytic features of natural killer (NK) cells. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells and suppress Graft versus Host Disease (GvHD). Our proprietary platform is designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. As such, we believe that our approach represents a highly versatile application for therapeutic development in cancer and immune diseases. We have leveraged our platform and manufacturing capabilities to develop a wholly owned pipeline for both native and engineered iNKT cells.

Pipeline

Our pipeline is guided by our commitment to provide patients around the world with access to best-in-class living drugs, with faster treatment timelines, wide range of cancers and other life threatening diseases

Product

Preclinical

Ph1

Ph2

Ph3

Native iNKT Cells
AGENT-797
Mechanism/Indication:
Solid Tumors
Anticipated Milestones:
H1-22: Phase 1 read-out
AGENT-797 + Checkpoint Antibodies
Mechanism/Indication:
Solid Tumors
including but not limited to NSCLC, HCC, SCCHN
Anticipated Milestones:
H1-22: Phase 1 read-out
AGENT-797
Mechanism/Indication:
r/r Multiple Myeloma
Anticipated Milestones:
Phase 1 Readout in Q4 ‘21
AGENT-797
Mechanism/Indication:
GvHD
Anticipated Milestones:
Phase 1 Readout in Q4 ‘21
AGENT-797
Mechanism/Indication:
ARDS Secondary to COVID-19
Anticipated Milestones:
IND Filing H1 ‘21
Engineered iNKT Cells
Mechanism/Indication:
BCMA-CAR-iNKT
Mechanism/Indication:
Stromal target-CAR-iNKT
Mechanism/Indication Product Preclinical Ph1 Ph2 Ph3 Anticipated Milestones
Native iNKT Cells
Solid TumorsAGENT-797
H1-22: Phase 1 read-out
Solid Tumors
including but not limited to NSCLC, HCC, SCCHN
AGENT-797 + Checkpoint Antibodies
H1-22: Phase 1 read-out
r/r Multiple MyelomaAGENT-797
Phase 1 Readout in Q4 ‘21
GvHDAGENT-797
Phase 1 Readout in Q4 ‘21
ARDS Secondary to COVID-19AGENT-797
IND Filing H1 ‘21
Engineered iNKT Cells
BCMA-CAR-iNKT
Stromal target-CAR-iNKT